Exelixis | EXEL - Trade Creditors


Exelixis reported $30.83M in Trade Creditors for its fiscal quarter ending in September of 2026.





Trade Creditors Change Date
Acadia Pharmaceuticals USD 16.33M 28.24M Sep/2026
Agios Pharmaceuticals USD 19.93M 3.58M Sep/2026
Akebia Therapeutics USD 7.61M 1.81M Sep/2026
Amgen USD 20.83B 17.97B Sep/2026
AstraZeneca USD 23.57B 679M Sep/2026
Bayer EUR 6.71B 314M Sep/2026
BioMarin Pharmaceutical USD 946.11M 32.44M Sep/2026
Bristol-Myers Squibb USD 4.63B 470M Sep/2026
Cytokinetics USD 25.96M 5.45M Sep/2026
Eisai JPY 87.53B 11.64B Jun/2026
Eli Lilly USD 5.79B 319M Sep/2026
Exelixis USD 30.83M 8.23M Sep/2026
Genmab DKK 116M 110M Jun/2026
Glaxosmithkline GBP 15.63B 1.3B Sep/2026
Incyte USD 235.37M 1.16B Sep/2026
Ionis Pharmaceuticals USD 27.11M 20.59M Sep/2026
MacroGenics USD 3.44M 845K Jun/2026
Merck USD 5.03B 1.2B Sep/2026
Moderna USD 259M 92M Sep/2026
Nektar Therapeutics USD 10.03M 744K Mar/2026
Neurocrine Biosciences USD 754.1M 612.1M Sep/2026
Novartis USD 4.24B 15M Sep/2026
Pfizer USD 4.07B 511M Sep/2026
Puma Biotechnology USD 6.39M 962K Sep/2025
Sanofi EUR 23.6B 888M Jun/2026
Takeda JPY 486.2B 39.41B Sep/2026
Ultragenyx Pharmaceutical USD 45M 6M Sep/2026
Xencor USD 6.65M 6M Sep/2026